CTIS2023-508634-34-00进行中（未招募）1 期
Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 antiviral treatment relief strategies, in patients co-infected with the HIV-1 and HBV viruses - ANRS0250s-BI-LIGHT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Inserm
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •HIV-1-HBV co-infection (positive HIV-1 serology associated with 2 positive HBsAg serologies within more than 6 months), ALT < 3N at pre-inclusion, For women of childbearing potential, negative pregnancy test and commitment to use effective contraception throughout the trial, Person affiliated with or benefiting from a social security system, Free, informed, written consent, signed by the person and the investigator at the latest on the day of inclusion and before any examination carried out as part of the study (article L1122-1-1 of the Public Health Code), Age = 18 years, Fibroscan less than 6 months < 9kPa, Current daily antiretroviral tritherapy not modified for = 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC – 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from oNNRTI = efavirenz, rilpivirine, etravirine, doravirine oPI/r = atazanavir/r ou darunavir/r oINSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir, Absence of documented HBV and HIV genotypic resistance compromising virologic control of any of the maintenance strategies. Patients with no genotypic history may be included), HIV CV < 50cp/ml for = 2 years (only 1 annual blip allowed if HIV CV < 200cp/ml and previous and subsequent viral loads are undetectable), HBV CV < 10 IU/ml for = 2 years (only 1 annual blip allowed if HBV CV < 200IU/ml and if previous and subsequent viral loads are undetectable), Have = 3 available measurements of HIV CV < 50cp/ml and HBV CV < 10 IU/mL over the past 24 months (including that of pre-inclusion, CD4 lymphocytes > 250/mm3 at pre-inclusion
排除标准
- •HIV-2 infection, Any condition (drug use, neurological, neuropsychiatric, etc.) that, in the judgment of the investigator, may compromise patient compliance and adherence to the protocol, Pregnant or breastfeeding woman or refusal of contraception, Major incapacity, legal protection, guardianship or curatorship., HIV and/or HBV genotype not compatible with dual therapy DTG-3TC or DRVr-3TC, HBeAg+., Fibrosis history at stage F3-F4 in pre-therapy evaluated by PBH, fibrotest and/or fibroscan with a value of Elastometry = 9kPa, Chronic active viral hepatitis C (HCV RNA positive), Delta co-infection, Alcohol consumption > 14 units/week for women and 21 units/week for men, Current treatment with chemo- or immunotherapy (including interferon or interleukins), Active opportunistic infection or acute treatment for opportunistic infection
研究者
相似试验
招募中
1 期
Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)ocally recurrent rectal cancerMedDRA version: 21.0Level: PTClassification code: 10038046Term: Rectal cancer recurrent Class: 100000004864CTIS2024-512526-28-00Catharina Ziekenhuis Stichting364
招募中
3 期
Multicenter, randomized, controlled, open-label, phase-III clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula after distal pancreatectomy (PREBOT trial)K86.8Other specified diseases of pancreasDRKS00010080Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial Director254
进行中（未招募）
1 期
Multicentre, randomized, controlled, open-label, multi-centre medico-economic study evaluating the efficacy of adding zoledronic acid to Stereotaxic radiotherapy in the treatment of vertebral metastasesPatients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy.MedDRA version: 20.0Level: LLTClassification code 10027484Term: Metastatic painSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027474Term: MetastaticSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10049038Term: Metastatic bone painSystem Organ Class: 100000004864EUCTR2019-001209-26-FRINSTITUT DE CANCEROLOGIE DE L'OUEST225
招募中
1 期
Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or denosumab to Stereotaxic radiotherapy in the treatment of vertebral metastases (ZOSTER)Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapyMedDRA version: 21.1Level: LLTClassification code: 10049038Term: Metastatic bone pain Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10027484Term: Metastatic pain Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10027474Term: Metastatic Class: 10029104CTIS2024-513248-27-00Institut De Cancerologie De L Ouest202
进行中（未招募）
不适用
Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin inhibitor (Sandimmun® Optoral or Prograf®) in stable renal transplant patients - APOLLOEUCTR2005-001013-18-DEovartis Pharma GmbH